BioMarin Pharma (BMRN) Tops Q4 EPS by 37c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $66.97 +3.29%
Revenue Growth %: +32.7%
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
RCBC, GASS, YSG, More
Revenue Growth %: +32.7%
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.92, $0.37 better than the analyst estimate of $0.55. Revenue for the quarter came in at $747 million versus the consensus estimate of $711.42 million.
GUIDANCE:
BioMarin Pharma sees FY2025 EPS of $4.20-$4.40, versus the consensus of $4.16. BioMarin Pharma sees FY2025 revenue of $3.1-3.2 billion, versus the consensus of $3.1 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
- Matrix Service wins FEED contract for Texas refinery tank farm
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $90; Piper Sandler: 'Remain Buyers'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
